articleTop 1% cited

Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Clinical Cancer Research · 2014 · Vol. 20(6) · pp. 1698–1705

Geoffrey R. Oxnard✉(Brigham and Women's Hospital)Cloud P. Paweletz(Brigham and Women's Hospital)Yanan Kuang(Dana-Farber Cancer Institute)Stacy L. Mach(Harvard University)Allison O’Connell(Dana-Farber Cancer Institute)Melissa M. Messineo(Harvard University)Jason J. Luke(Dana-Farber Cancer Institute)Mohit Butaney(Dana-Farber Cancer Institute)Paul T. Kirschmeier(Dana-Farber Cancer Institute)David M. Jackman(Harvard University)Pasi A. Jänne(Harvard University)

View via DOI Publisher page

Abstract

Noninvasive genotyping of cfDNA using ddPCR demonstrates assay qualities that could allow effective translation into a clinical diagnostic. Serial quantification of plasma genotype allows noninvasive assessment of response and resistance, including detection of resistance mutations up to 16 weeks before radiographic progression.

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Lung Cancer Research StudiesErlotinibKRASLung cancerDigital polymerase chain reactionT790MGenotypingGenotypeLiquid biopsyCancerCell-free fetal DNA

MeSH terms

Cell-Free SystemDNAGenetic TestingGenotypeHumansLung NeoplasmsMutationPlasmaROC CurvePolymerase Chain ReactionDrug Resistance, NeoplasmArea Under CurveErbB Receptors

Citations

776

FWCI

33.96

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma